Pharmacists' role in reporting international perspective

被引:114
作者
van Grootheest, K
Olsson, S
Couper, M
de Jong-van den Berg, L
机构
[1] Netherlands Pharmacovigilance Ctr Lareb, NL-5237 MH Shertogenbosch, Netherlands
[2] WHO, Collaborating Ctr Int Drug Monitoring, Uppsala, Sweden
[3] WHO, Programme Int Drug Monitoring, CH-1211 Geneva, Switzerland
[4] GUIDE, Dept Social Pharm & Pharmacoepidemiol, Groningen, Netherlands
关键词
pharmacists; adverse drug reactions; reporting; international; WHO;
D O I
10.1002/pds.897
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 [公共卫生与预防医学]; 120402 [社会医学与卫生事业管理];
摘要
Introduction The participation of the pharmacist in national spontaneous reporting systems for adverse drug reactions (ADRs) has not always been a matter of course. Even today, there are a number of countries, in particular the Scandinavian countries, where pharmacists are not authorised to report ADRs. In those countries in which they are allowed to report, they do not always use this opportunity. Methods We have conducted a review of the literature to investigate the involvement of pharmacists in ADR reporting. In addition, we evaluated the pharmacists' actual contributions in 2001 by means of an international questionnaire-based survey among the countries participating in the WHO Drug Monitoring Programme in September 2002. Apart from the numbers of pharmacists' reports, respondents were asked to indicate their assessment of both the quality and the significance of the contribution. Of the 68 participating countries, 41 responded by returning the questionnaire. Results and conclusions The appreciation of pharmacists' ADR reports is high in those countries that have more experience with greater numbers of pharmacists' reports. The countries that received fewer reports from pharmacists gave lower scores to their contribution. If the specific contribution pharmacists can make to the quantity and quality of ADR reports were to be exploited to a greater extent, this could lead to a substantial improvement of the international adverse drug reactions reporting system. Copyright (C) 2003 John Wiley Sons, Ltd.
引用
收藏
页码:457 / 464
页数:8
相关论文
共 44 条
[1]
Ahmad Syed Rizwanuddin, 1996, Pharmacoepidemiology and Drug Safety, V5, P1
[2]
[Anonymous], 2011, INT J PHARM PRACT, DOI DOI 10.1111/J.2042-7174.1999.TB00955.X
[3]
[Anonymous], 2002, Safety of Medicines - A Guide to Detecting and Reporting Adverse Drug Reactions - Why Health Professionals Need to Take Action
[4]
*ASHP, 1992, 199293 ASHP
[5]
Beard K, 2001, ADVERSE DRUG REACTIO, P1
[6]
*CAN SOC HOSP PHAR, 1990, STAND PRACT
[7]
DEBASA F, BR J CLIN PHARM, V54, P334
[8]
Prospective cohort study of adverse events monitored by hospital pharmacists [J].
Emerson, A ;
Martin, RM ;
Tomlin, M ;
Mann, RD .
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2001, 10 (02) :95-103
[9]
ESCH AF, 1972, INT DRUG MONITORING, P44
[10]
[FDA Food and Drug Administration], 1992, GUID POSTM REP ADV D